Although the function of Cygb in vivo remains largely unknown, decreased expression of Cygb and the hypermethylation of the Cygb promoter has been reported in patients with tylosis, non–small-cell lung carcinomas, head and neck cancers, ovarian cancers, and breast cancers [9-12]. Here, CYGB is linked to ovarian cancer.